[go: up one dir, main page]

WO2014036438A3 - Live brucellosis vaccines comprising attenuated brucella mutants - Google Patents

Live brucellosis vaccines comprising attenuated brucella mutants Download PDF

Info

Publication number
WO2014036438A3
WO2014036438A3 PCT/US2013/057578 US2013057578W WO2014036438A3 WO 2014036438 A3 WO2014036438 A3 WO 2014036438A3 US 2013057578 W US2013057578 W US 2013057578W WO 2014036438 A3 WO2014036438 A3 WO 2014036438A3
Authority
WO
WIPO (PCT)
Prior art keywords
brucella
vaccines
mutants
live
attenuated brucella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/057578
Other languages
French (fr)
Other versions
WO2014036438A2 (en
Inventor
David W. Pascual
Xinghong YANG
Beata CLAPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montana State University Bozeman
Original Assignee
Montana State University Bozeman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montana State University Bozeman filed Critical Montana State University Bozeman
Publication of WO2014036438A2 publication Critical patent/WO2014036438A2/en
Publication of WO2014036438A3 publication Critical patent/WO2014036438A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides Brucella vaccines that protect against Brucella infections and brucellosis. These vaccines can provide cross-resistance to protect against infections by other Brucella strains. Also provided are the Brucella strains that can be used in the vaccines. Methods of inducing immunity to a Brucella infection in a mammal and of differentiating immunized mammals from unimmunized mammals are also provided.
PCT/US2013/057578 2012-08-30 2013-08-30 Live brucellosis vaccines comprising attenuated brucella mutants Ceased WO2014036438A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261695205P 2012-08-30 2012-08-30
US61/695,205 2012-08-30
US201361783367P 2013-03-14 2013-03-14
US61/783,367 2013-03-14

Publications (2)

Publication Number Publication Date
WO2014036438A2 WO2014036438A2 (en) 2014-03-06
WO2014036438A3 true WO2014036438A3 (en) 2014-04-24

Family

ID=50184661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/057578 Ceased WO2014036438A2 (en) 2012-08-30 2013-08-30 Live brucellosis vaccines comprising attenuated brucella mutants

Country Status (1)

Country Link
WO (1) WO2014036438A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103952428B (en) * 2014-04-11 2016-08-17 中国人民解放军军事医学科学院军事兽医研究所 The preparation method of brucella bacterium shell vaccine strain
CN113025640B (en) * 2021-03-17 2023-09-12 天康生物制药有限公司 Preparation method and application of brucella outer membrane vesicle
CN114075551B (en) * 2021-06-11 2024-01-26 华中农业大学 Monoclonal antibody of brucella lipopolysaccharide of sarin mouse species and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241188A1 (en) * 2003-02-28 2004-12-02 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services Recombinant human metapneumovirus and its use
US20110033492A1 (en) * 2007-12-19 2011-02-10 Dominic Charles Jenner Vaccines for brucellosis
US20120202270A1 (en) * 2008-10-30 2012-08-09 Schurig Gerhardt G Producing an immune response for reducing the risk of developing brucellosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241188A1 (en) * 2003-02-28 2004-12-02 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services Recombinant human metapneumovirus and its use
US20110033492A1 (en) * 2007-12-19 2011-02-10 Dominic Charles Jenner Vaccines for brucellosis
US20120202270A1 (en) * 2008-10-30 2012-08-09 Schurig Gerhardt G Producing an immune response for reducing the risk of developing brucellosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PASCUAL, DW.: "Brucellosis Vaccine", 19 August 2011 (2011-08-19), Retrieved from the Internet <URL:http://portal.nifa.usda.gov/web/crisprojectpages/0219665-brucellosis-vaccine-mt.html> [retrieved on 20140212] *

Also Published As

Publication number Publication date
WO2014036438A2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
EP3148576B8 (en) Vaccine composition against streptococcus suis infection
WO2013054199A3 (en) Cmv antigens and uses thereof
ZA201500784B (en) Mycobacterial antigen vaccine
HUE047085T2 (en) Preparations and methods related to the Clostridium difficile mutant toxin
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
IL244642B (en) Broadband graphene-based optical limiter for the protection of backside illuminated cmos detectors
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
HK1219045A1 (en) Compositions and methods of enhancing immune responses to enteric pathogens
PH12015501101B1 (en) Method for eliciting an immune response to an immunogen
HUE047484T2 (en) Compositions and methods for enhancing the immune response against eimeria or limiting eimeria infection
WO2013084071A3 (en) Clostridium difficile toxin-based vaccine
MX2017016401A (en) Immunogenic compositions.
EP3024482A4 (en) Methods for diagnosing and treating immune disease
EP3113859A4 (en) Cerium (iv) oxide with exceptional arsenic removal properties
WO2012170097A3 (en) Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
WO2014036438A3 (en) Live brucellosis vaccines comprising attenuated brucella mutants
HK1254514A1 (en) Methods and compositions for enhancing immune response to vaccination
WO2011100408A3 (en) Serologic correlates of protection against bacillis anthracis infection
EP3538197A4 (en) Devices and methods for enhancing immunogenicity to intradermal vaccination
MX2019008779A (en) Pseudomonas antigens and antigen combinations.
WO2014165164A3 (en) Compositions and methods for treating autoimmune diseases
HK1224187A1 (en) Vaccine compositions for drug addiction
WO2014166501A3 (en) Use of immune suppressive peptides as adjuvants
ES2586979A1 (en) Live vaccines attenuated by staphylococcus aureus (Machine-translation by Google Translate, not legally binding)
IL234629B (en) An immunogenic composition for use in a method of raising a protective immune response against h. influenzae infection and a process of preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13832803

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13832803

Country of ref document: EP

Kind code of ref document: A2